Mandate

Vinge advises Active Biotech in its new issue

April 06, 2009

Vinge has advised Active Biotech in its new issue of shares subject to pre-emption rights for the existing shareholders. Under the new issue, which is underwritten in its entirety by the principal shareholders MGA Holding and Nordstjernan, Active Biotech receives approximately SEK 256 million.

Vinge’s team was led by Erik Sjöman who was assisted by, among others, associates Christian Lindhé, Karolina Tjärnberg Jansson and Maria Doeser (tax law advice).

Related

Vinge advises Adelis Equity Partners on the establishment of a continuation fund

Vinge has advised Adelis Equity Partners on the establishment of a continuation fund to Adelis Equity Partners Fund II. The continuation fund is a so-called dual-asset vehicle which will invest in Presto and HVD Group (Hantverksdata) – both current portfolio companies of Adelis Equity Partners Fund II. The continuation fund, in which HarbourVest Partners will be the largest investor, will have EUR 430m in commitments and will invest alongside Adelis Equity Partners Fund III and the Adelis team.
February 21, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Wavecon

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Wavecon AB (”Wavecon”).
February 14, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Projektstaben

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Projektstaben i Sverige AB (”Projektstaben”).
February 14, 2024